Changes in membrane glycoproteins of circulating platelets after coronary stent implantation

Heart

Volumn 76, Issue 2, 1996, Pages 166-172

  Gawaz, M ^a   Neumann, F J ^a   Ott, I ^a   May, A ^a   Rudiger S ^a   Schomig A ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Angioplasty; Coronary stent implantation; Membrane glycoproteins; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; FIBRINOGEN; FIBRINOGEN RECEPTOR; HEPARIN; PADGEM PROTEIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL ARTICLE; CORONARY ARTERY DILATATION; FEMALE; FLOW CYTOMETRY; HUMAN; IMPLANTATION; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0029758005     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.76.2.166     Document Type: Article

References (40)

1. Herrmann HC, Buchbinder M, Clemen MW, Fischman D, Goldberg S, Leon MB, et al. Emergent use of balloon-expandable coronary artery stenting for failed percutaneous transluminal coronary angioplasty. Circulation 1992;86:812-9.
2. Kastrati A, Schömig A, Dietz R, Neumann FJ, Richardt G. Time course of restenosis during the first year after emergency coronary stenting. Circulation. 1993;87: 1498-1505.
3. Schömig A, Kastrati A, Dietz R, Rauch B, Neumann FJ, Katus HH, et al. Emergency coronary stenting for dissection during percutaneous transluminal coronary angioplasty: angiographic follow-up after stenting and after repeat angioplasty of the stented segment. J Am Coll Cardiol 1994;23:1053-60.
4. Sigwart U, Urvan P, Golf S, Kaufmann U, Imbert C, Fischer A, et al. Emergency stenting for acute occlusion after coronary balloon angioplasty. Circulation 1988;78: 1121-7.
5. Schömig A, Kastrati A, Mudra H, Blasini R, Schühlen H, Klauss V, et al. Four-year experience with Palmaz-Schatz stenting in coronary angioplasty complicated by dissection with threatened or present vessel closure. Circulation 1994;90:2716-24.
6. Serruys PW, de Jaegere P, Kiemeneij F, Magaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489-95.
7. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Detre K, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496-501.
8. Topol EJ. Caveats about elective coronary stenting. N Engl J Med 1994;331:539-41.
9. Schatz RA, Baim DS, Leon M, Ellis SG, Goldberg S, Hirshfeld JW, et al. Clinical experience with the Palmaz-Schatz coronary stem. Initial results of a multicenter study. Circulation 1991;83:148-61.
10. Haude M, Erbel R, Issa H, Straub U, Rupprecht HJ, Treese N, et al. Subacute thrombotic complications after intracoronary implantation of Palmaz-Schatz stents. Am Heart J 1993;126:15-22.
11. Schatz AS, Baim DS, Leon M, Ellis SG, Goldberg S, Hirshfeld JW, et al. Clinical experience with Palmaz-Schatz coronary stent. Circulation 1991;83:148-61.
12. Harker LA. Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty. Am J Cardiol 1987;60:20B-28B.
13. Fuster V, Badimon L, Cohen M, Ambrose JA, Badimon JJ, Chesebro J. Insights into pathogenesis of acute ischemic syndromes. Circulation 1988;77:1213-20.
14. George JN, Nurden AT, Phillips DR. Molecular defects in interactions of platelets with the vessel wall. N Engl J Med 1984;311:1084-98.
15. McEver RP. The clinical significance of platelet membrane glycoproteins. Hematol/Oncol Clin N Am 1990;4:87-103.
16. Becker RC. Antiplatelet therapy in coronary heart disease. Arch Pathol Lab Med 1993;117:89-96.
17. Gershlick AH. Principles of platelet inhibitor therapy-where we stood in 1993. Eur Heart J 1994;15:149-55.
18. Ruggeri ZM. New insights into mechanisms of platelet adhesion and aggregation. Sem Hematol 1994;31:229-39.
19. Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb-IIIa complex. Blood 1988;71:831-43.
20. Plow EF, Ginsberg MH. Cellular adhesion. GPIIb-IIIa as a prototypic adhesion receptor. In: Coller BS, ed. Progress in hemostasis and thrombosis. Philadelphia: Saunders, 1989;117-56.
21. Leung L and Nachman R. Molecular mechanisms of platelet aggregation. Ann Rev Med 1986;37:179-86.
22. Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987;70:307-15.
23. Abrams C, Shattil SJ. Immunological detection of activated platelets in clinical disorders. Thromb Haemost 1991; 65:467-73.
24. Rinder CS, Mathew JP, Rinder HM, Bonan J, Ault AK, Smith BR. Modulation of platelet surface adhesion receptors during cardiopulmonary bypass. Anesthesiology 1991;75:563-70
25. Scharf RE, Tomer A, Mrzec UM, Teirstein PS, Ruggeri ZM, et al. Activation of platelets in blood perfusing angioplasty-damaged coronary arteries. Flow cytometric detection. Arterioscl Thromb 1992;12:1475-87.
26. Tschoepe D, Schultheiß HP, Kolarov P, Schwippert B, Dannehl K, Nieuwenhuis HK, et al. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation 1993;88: 37-42.
27. Nurden AT, Macchi L, Bihour C, Durrieu C, Besse P, Nurden P. Markers of platelet activation in coronary heart disease patients. Eur J Clin Invest 1994;24:42-5.
28. Gawaz M, Fateh-Moghadam S, Pilz G, Gurland HJ. Werdan K. Severity of multiple organ failure but not of sepsis correlates with irreversible platelet degranulation. Infection 1995;23:16-27.
29. Gawaz MP, Dobos G, Späth M, Schollmeyer P, Gurland HJ, Mujais SK. Impaired function of platelet membrane glycoprotein IIb-IIIa in end-stage renal disease. J Am Soc Nephrol 1994;5:36-46.
30. Gawaz MP, Mujais SK, Schmidt B, Gurland HJ. Platelet-leukocyte aggregation during hemodialysis. Kidney Int 1994;46:489-95.
31. Gawaz M, Ott I, Reininger AJ, Neumann FJ. Effects of magnesium on platelet aggregation and adhesion. Magnesium modulates surface expression of glycoproteins on platelets in vitro and ex vivo. Thromb Haemost 1994;72:912-8.
32. Gawaz M, Neumann FJ, Ott I, Schiessler A, Schömig A. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 1996;93:229-37.
33. Ginsberg MH, Frelinger AL, Lam SCT, Forsyth J, McMillan R, Plow EF, et al. Analysis of platelet aggregation disorders based on flow cytometric analysis of platelet membrane glycoprotein IIb-IIIa with conformation specific monoclonal antibodies. Blood 1990;76: 2017-23.
34. The EPIC Inverstigators: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330:956-61.
35. Weiss HJ. von Willebrand factor and platelet function. In: Ruggeri ZM, Fulcher CA, Ware J, eds. Progress in vascular biology, hemostasis, and thrombosis. Ann N Y Acad Sci 1991;614:125-37.
36. Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK. A cascade model for restenosis. A special case of atherosclerosis progression. Circulation 1992;86:III-47-III-52.
37. Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L. Effects of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980;65:65-73.
38. Landolfi R, DeCandia E, Rocca B, Ciabattoni G, Antinori A, Masetti R, et al. Effects of unfractionated and low molecular weight heparins on platelet thromboxane biosynthesis "in vivo". Thromb Haemost 1994;72:942-6.
39. Neumann FJ, Ott I, Gawaz M, Puchno G, Schömig A. Neutrophil and platelet activation at balloon-infrared coronary artery plaque in patients undergoing angioplasty. J Am Coll Cardiol 1996;27:819-24.
40. Krupski WC, Bass A, Cadroy Y, Kelly AB, Harker IA, Hanson SR. Antihemostatic and antithrombotic effects of monoclonal antibodies against von Willebrand factor in nonhuman primates. Surgery 1992;112:433-9.